Linagliptin,
does it really help with Lower 24-week HbA1c and fasting plasma glucose in adults with inadequately controlled type 2 diabetes?
research showsLinagliptin is rated C because it lowers 24-week HbA1c and fasting plasma glucose versus placebo in adults with inadequately controlled type 2 diabetes. In a representative manufacturer-sponsored phase 3 trial, placebo-adjusted HbA1c fell by 0.69 percentage points and fasting plasma glucose by 1.3 mmol/L. Both are surrogate rather than complication outcomes, the effect is modest, and the large CARMELINA outcome trial showed no reduction in major cardiovascular events or weight benefit. The efficacy grade reflects the surrogate-endpoint ceiling; pancreatitis, severe joint pain, and rare bullous pemphigoid are recorded separately under safety.
ads claimPromotion can expand improved glucose numbers into prevention of diabetes complications, heart protection, or weight loss. Direct evidence supports 24-week HbA1c and fasting-glucose reduction; cardiovascular protection and weight loss are separate clinical claims that are not established.
Useful facts when choosing a product
- Linagliptin is a prescription DPP-4 inhibitor for type 2 diabetes, commonly dosed at 5 mg once daily in adults, while the prescriber determines the actual regimen and combination therapy.
- Because renal elimination is limited, linagliptin usually does not require dose adjustment for kidney function, but that does not mean it treats kidney disease or improves renal clinical outcomes.
- Hypoglycemia risk is low with monotherapy but can increase when linagliptin is combined with a sulfonylurea or insulin.
- Overall tolerability was generally favorable in large trials, but persistent severe abdominal pain, severe joint pain, or blistering skin lesions warrant prompt contact with the prescriber because pancreatitis, severe arthralgia, and rare bullous pemphigoid are recognized concerns.
What the research actually shows
The manufacturer-sponsored multicenter phase 3 trial by Del Prato and colleagues randomized 503 treatment-naive participants or participants inadequately controlled on one oral drug to linagliptin 5 mg or placebo. At 24 weeks, placebo-adjusted HbA1c changed by -0.69 percentage points and fasting plasma glucose by -1.3 mmol/L, without weight gain. Other add-on phase 3 trials generally reported HbA1c reductions of about 0.5 to 0.7 percentage points but were concentrated in the same manufacturer development program. CARMELINA followed 6,979 participants at high cardiovascular and renal risk for a median 2.2 years. Linagliptin was noninferior to placebo for three-point MACE but not superior, and the kidney composite was not reduced. These findings do not negate 24-week glucose lowering, but they prevent extrapolation of the surrogate change into cardiovascular or weight benefit.
Why this is classified as C (55)
Placebo-controlled trials repeatedly show about a 0.5-to-0.7-percentage-point reduction in 24-week HbA1c plus lower fasting glucose. Both are surrogates, the effect is modest, evidence is concentrated in the manufacturer program, and CARMELINA did not show cardiovascular or weight benefit. Consistency with the surrogate-endpoint ceiling applied to verdicts 914 and 902 gives C with 55 points. Pancreatitis, arthralgia, and bullous pemphigoid remain safety issues independent of the efficacy score.
Counterpoint. Linagliptin can be a weight-neutral add-on glucose-lowering option when metformin or other therapy is insufficient. Cardiovascular, kidney, and weight priorities may favor a different class with demonstrated outcome benefit, so treatment should not be started or stopped without the prescriber.
Rejudgment record. New verdict — Accepted placebo-controlled improvement in 24-week HbA1c and fasting glucose, but applied the rule ① ceiling of C because both are surrogate endpoints, the effect is modest, trials are concentrated in the manufacturer program, and CARMELINA showed no cardiovascular or weight benefit; aligned with surrogate prescription-drug verdicts 914 for tirzepatide HbA1c and 902 for TAF HBV DNA. Sitagliptin verdict 784 at D concerned the separately contradicted extrapolation from HbA1c to lower MACE
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Lower HbA1c at 24 weeks | C | A reduction of about 0.5 to 0.7 percentage points versus placebo is reproducible but remains a surrogate rather than a complication outcome. |
| Lower fasting plasma glucose at 24 weeks | C | Placebo-controlled trials show a reduction, but the outcome is a surrogate and the effect is modest. |
| Cardiovascular or weight benefit accompanying glucose lowering | D | CARMELINA was cardiovascularly neutral and no weight-loss benefit is established, so these outcomes are separate from glycemic surrogates. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Del Prato S et al. 2011 | Multicenter randomized double-blind placebo-controlled phase 3 trial | 167 | Sponsored by Boehringer Ingelheim with company-employed coauthors | Primary 24-week HbA1c, fasting and postprandial glucose, weight, and safety | Placebo-adjusted HbA1c improved by -0.69 percentage points and fasting glucose by -1.3 mmol/L, without weight gain. | Key direct 24-week glycemic-surrogate evidence |
| Owens DR et al. 2011 | Randomized double-blind placebo-controlled add-on trial | 1,058 | Boehringer Ingelheim manufacturer program | Twenty-four-week HbA1c, fasting glucose, weight, and hypoglycemia | Placebo-adjusted HbA1c was -0.62 percentage points and fasting glucose -0.7 mmol/L, with no significant weight change. | Add-on replication with manufacturer concentration |
| Rosenstock J et al.; CARMELINA Investigators. 2019 | Multinational randomized placebo-controlled cardiovascular and kidney outcome trial | 6,979 | Sponsored by Boehringer Ingelheim and Eli Lilly | Primary three-point MACE, kidney composite, and safety | Three-point MACE was noninferior but not reduced, HR 1.02 (95% CI 0.89 to 1.17), and the kidney composite did not differ. | Large hard-outcome evidence of cardiovascular and kidney neutrality |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Linagliptin x lower 24-week HbA1c and fasting plasma glucose in inadequately controlled type 2 diabetes — Evidence Grade C·55. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/linagliptin-24-week-hba1c-fasting-glucose/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.